The Role of Hepatocyte Growth Factor (HGF) in Insulin Resistance and Diabetes

• Published in: Frontiers in endocrinology (Lausanne) Vol. 9; p. 503
• Main Authors: Oliveira, Alexandre G, Araújo, Tiago G, Carvalho, Bruno de Melo, Rocha, Guilherme Z, Santos, Andrey, Saad, Mario J A
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 30.08.2018
• Subjects: diabetes; Endocrinology; hepatocyte growth factor; HGF; inflammation; insulin resistance; obesity; inflammation; HGF; hepatocyte growth factor; diabetes; insulin resistance; beta cells; obesity
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2018.00503

In obesity, insulin resistance (IR) and diabetes, there are proteins and hormones that may lead to the discovery of promising biomarkers and treatments for these metabolic disorders. For example, these molecules may impair the insulin signaling pathway or provide protection against IR. Thus, identifying proteins that are upregulated in IR states is relevant to the diagnosis and treatment of the associated disorders. It is becoming clear that hepatocyte growth factor (HGF) is an important component of the pathophysiology of IR, with increased levels in most common IR conditions, including obesity. HGF has a role in the metabolic flux of glucose in different insulin sensitive cell types; plays a key role in β-cell homeostasis; and is capable of modulating the inflammatory response. In this review, we discuss how, and to what extent HGF contributes to IR and diabetes pathophysiology, as well as its role in cancer which is more prevalent in obesity and diabetes. Based on the current literature and knowledge, it is clear that HGF plays a central role in these metabolic disorders. Thus, HGF levels could be employed as a biomarker for disease status/progression, and HGF/c-Met signaling pathway modulators could effectively regulate IR and treat diabetes.